From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...

Recombinant antibodies are invented antibodies formed by using recombinant DNA technology. While traditional monoclonal ...

The partnership, which began in December 2022, now provides AbbVie access to AbCellera’s TCE platform for the development of therapeutic antibodies targeting tumours. AbbVie will have the rights ...

The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

A review of recent trends and remaining challenges in bispecific antibody (bsAb) production has been published.

The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

A new study shows how an anticancer drug triggers an "outside in" signal that gets it sucked into a cancer cell. The work, ...

A new antibody therapy effectively protects monkeys from severe H5N1 avian flu, offering hope for a universal flu vaccine and ...